Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).

Cancer Res Treat · 2018 · PMC6192917 · PMID 29334610

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A recent phase II randomized study reported that dovitinib in combination with fulvestrant showed a trend to improve median PFS compared with fulvestrant alone in FGF pathway amplified subgroup (10.9 months vs. 5.5 months) [ 22 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.